SARS-CoV-2
456
5
18
243
Key Insights
Highlights
Success Rate
84% trial completion
Published Results
79 trials with published results (17%)
Research Maturity
243 completed trials (53% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
10.3%
47 terminated out of 456 trials
83.8%
-2.7% vs benchmark
14%
62 trials in Phase 3/4
33%
79 of 243 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 243 completed trials
Clinical Trials (456)
Molnupiravir and COVID-19 Mortality Reduction in the Omicron Era
Secondary Databased Post-marketing Surveillance Study of BNT162b2
Use and Effectiveness of COVID-19 Vaccines Using State Vaccine Registries and Insurance Claims Data
A Study to Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection
POC Performance Evaluation of LumiraDx SARS-CoV-2 Ag Ultra and SARS-CoV-2 & Flu A/B Tests.
French Single Centre Experience of Critically Ill Patients With Covid 19
Evaluation of Quickly Diagnostic Saliva Tests for SARS-CoV-2
Clinical Validation of the LumiraDx SARS-CoV-2 & Flu A/B Combo Test
Study on Safety and Efficacy of Two Doses of PRS CK STORM in the Modulation of the Cytokine Storm in Patients With Acute Respiratory Infection Caused by SARS-Cov-2, Influenza A, Influenza B and Respiratory Syncytial Virus (RSV)
Covid-19 in Patients With Chronic Inflammatory Rheumatism, Auto-immune or Auto-inflammatory Rare and Non-rare Diseases
Longitudinal Study of Covid-19 Infection Among HCW in a French University Hospital
Rutgers COVID-19 Cohort Study
Trial of COVID-19 Outpatient Treatment in Individuals With Risk Factors for Aggravation
A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19)
Myocardial Injury and Outcomes Following COVID-19 Vaccination (MYOVAX Study)
Korea Comirnaty Post-marketing Surveillance
COVID-19 and ICU-acquired MDR Bacteria
PROTECT-APT 1: Early Treatment and Post-Exposure Prophylaxis of COVID-19
Post-marketing Surveillance (PMS) Use-Result Surveillance With SPIKEVAX BIVALENT, SPIKEVAX X Injection, SPIKEVAX JN Injection and SPIKEVAX IN PRE-FILLED SYRINGE
Low-Dose Radiotherapy For Patients With SARS-COV-2 (COVID-19) Pneumonia